Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) gapped up prior to trading on Thursday . The stock had previously closed at $51.21, but opened at $51.76. Ultragenyx Pharmaceutical shares last traded at $52.66, with a volume of 455,661 shares traded.

RARE has been the topic of a number of recent research reports. Jefferies Group restated a “buy” rating and issued a $109.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. Leerink Swann restated a “buy” rating and issued a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Finally, Credit Suisse Group AG restated a “buy” rating and issued a $101.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 25th. Three equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $99.32.

The company’s market capitalization is $2.05 billion. The firm has a 50 day moving average price of $60.45 and a 200 day moving average price of $67.49.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.29) by $0.06. During the same quarter in the prior year, the business earned ($0.63) earnings per share. The business’s revenue for the quarter was up .0% on a year-over-year basis. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post ($5.79) EPS for the current fiscal year.

In related news, insider Sunil Agarwal sold 650 shares of the firm’s stock in a transaction on Monday, June 20th. The stock was sold at an average price of $54.16, for a total transaction of $35,204.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $59.95, for a total value of $1,199,000.00. Following the sale, the chief executive officer now directly owns 526,704 shares in the company, valued at approximately $31,575,904.80. The disclosure for this sale can be found here.

Other hedge funds have modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of Ultragenyx Pharmaceutical by 14.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,774,736 shares of the biopharmaceutical company’s stock valued at $199,090,000 after buying an additional 219,746 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock valued at $84,739,000 after buying an additional 109,724 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of Ultragenyx Pharmaceutical by 14.6% in the fourth quarter. New York State Common Retirement Fund now owns 56,877 shares of the biopharmaceutical company’s stock valued at $6,380,000 after buying an additional 7,240 shares during the last quarter. Columbus Circle Investors increased its stake in shares of Ultragenyx Pharmaceutical by 57.1% in the fourth quarter. Columbus Circle Investors now owns 236,010 shares of the biopharmaceutical company’s stock valued at $26,476,000 after buying an additional 85,781 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Ultragenyx Pharmaceutical by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 71,172 shares of the biopharmaceutical company’s stock valued at $7,984,000 after buying an additional 1,100 shares during the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.